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ABSTRACT 
 
Intracellular delivery of cell-impermeable compounds in a variety cells using 
delivery systems have been extensively studied in recent years. Obtaining desirable 
cellular uptake levels often requires the administration of high quantities of drugs to 
achieve the expected intracellular biological effect. Thus, improving the translocation 
process across the plasma membrane will significantly reduce the quantity of required 
administered drug and consequently minimize the side effects in most of the cases. 
Efficient delivery of these molecules to the cells and tissues is a difficult challenge. 
Compounds with low cellular permeability are commonly considered to be of limited 
therapeutic value. Over the past few decades, several biomedical carriers, such as 
polymers, nanospheres, nanocapsules, liposomes, micelles, peptides and dendrimers have 
been widely used to deliver therapeutic and diagnostic agents to the cells.  Biomaterials 
generated from nano-scale compounds have shown some promising data for delivery of 
many compounds in a number of diseases, such as viral infections, cancer, and genetic 
disorders. Although much progress has been achieved in this field, many challenges still 
remain, such as toxicity and limited stability. 
 Liposomes suffer from poor stability in the bloodstream and leakage during 
storage. They tend to aggregate and fuse with or leak entrapped drugs, especially highly 
hydrophilic small molecules. For solid lipid nanoparticles (SLNs), drug expulsion after 
polymorphic transition during storage, inadequate loading capacity, and relatively high 
water content of the dispersions have been observed.  
  
 Poly lactic-co-glycolic acid (PLGA) degrades in the body producing its original 
monomers of lactic acid and glycolic acid, which are the by-products of various 
metabolic pathways. However, this acidic microenvironment that occurs during 
degradation could negatively affect the stability of the loaded compound. Dendrimers 
can carry drugs as complexes or as conjugates although one limitation lies in the effort of 
controlling the rate of drug release. The encapsulated or complexed drugs tend to be 
released rapidly (before reaching the target site) and in the dendrimer–drug conjugates, it 
is the chemical linkage that controls the drug release. Thus, future studies in this field are 
urgently required to create more efficient and stable biomaterials.  
Peptides are considered as efficient vectors for achieving optimal cellular uptake. 
The potential use of peptides as drug delivery vectors received much attention by the 
discovery of several cell-penetrating peptides (CPPs). The first CPPs, discovered in 1988, 
were sequences from HIV-1 encoded TAT protein, TAT (48–60), and penetrated very 
efficiently through cell membranes of cultured mammalian cells. CPPs are a class of 
diverse peptides, typically with 8–52 amino acids, and unlike most peptides, they can 
cross the cellular membrane with more efficiency. CPPs have also shown to undergo self-
assembly and generate nanostructures.
 
The generation of self-assembled peptides and 
nanostructures occur through various types of interactions between functional groups of 
amino acid residues, such as electrostatic, hydrophobic, and hydrogen bonding. 
Appropriate design and functionalization of peptides are critical for generating 
nanostructures. 
 
  
Chemically CPPs are classified into two major groups: linear and cyclic peptides. 
It has been previously reported that linear peptides containing hydrophilic and 
hydrophobic amino acids could act as membrane protein stabilizers.
 
These compounds 
are short hydrophilic or amphiphilic peptides that have positively charged amino acids, 
such as arginine, lysine or histidine, which can interact with the negative charge 
phospholipids layer on the cell membrane and translocate the cargo into the cells.  
Conjugation to cationic linear CPPs, such as TAT, penetratin, or oligoarginine 
efficiently improves the cellular uptake of large hydrophilic molecules, but the cellular 
uptake is predominantly via an unproductive endosomal pathway. Therefore, the 
biological effect is very limited, as the compounds are trapped in these compartments and 
cannot reach their biological targets in the cytoplasm or the nucleus. Mechanisms that 
promote endosomal escape or avoid endosomal route are required for improving 
bioavailability. Highly cationic CPPs preferentially interact with particular cell types,
 
have limited plasma half-life, show toxicity, do not cross multicellular barriers such as 
vasculature epithelia or the blood-brain barrier, and efficient cargo delivery requires 9-15 
arginine residues. Highly cationic CPPs are, therefore not ideal small molecule drug 
delivery vehicles. Linear CPPs are susceptible to hydrolysis by endogenous peptidases. 
Conjugation to cationic CPPs, such as TAT, penetratin, or oligoarginine efficiently 
improves the cellular uptake of large hydrophilic molecules, but the cellular uptake 
occurs predominantly via an unproductive endosomal pathway. Therefore, the biological 
effect is very limited, as the compounds are trapped in these compartments and cannot 
reach their biological targets in the cytoplasm or the nucleus.  
  
Mechanisms that promote endosomal escape or avoid endosomal route are 
required for improving bioavailability. Highly cationic CPPs preferentially interact with 
particular cell types,
 
have limited plasma half-life, show toxicity, do not cross 
multicellular barriers such as vasculature epithelia or the blood-brain barrier, and efficient 
cargo delivery requires 9-15 arginine residues. Highly cationic linear CPPs are, therefore, 
have not become optimized as small molecule drug delivery vehicles.  
On the other hand, cyclic peptides containing hydrophilic and hydrophobic amino 
acids have shown greater potential as drug delivery tools due to their enhanced chemical 
and enzymatic stability. Parang's laboratory has reported that Amphiphilic Cyclic 
Peptides (ACPs) containing positively charged arginine and hydrophobic tryptophan 
residues as potential candidates for drug delivery. Cyclic peptides have several benefits 
compared to linear peptides, such as rigidness of structure and stability against 
proteolytic enzymes. The rigidity of the structure can enhance the binding affinity of 
ligands toward receptors by reducing the freedom of possible structural conformations. 
Cyclic peptides are also present in nature and have been developed as therapeutics. 
Cyclosporine, gramicidin S, polymoxin B, and daptomycin are well-known examples of 
cyclic peptide drugs. Parang's laboratory designed amphiphilic cyclic CPPs containing 
alternative tryptophan and arginine residues as the positively charged and hydrophobic 
residues, respectively. The peptides were efficient in improving the cellular delivery of 
anticancer and antiviral drugs.  
 
 
  
The cellular uptake mechanism of CPPs into cells is still a matter of some debate. 
The cellular entry of CPP can be influenced by the type of CPP, the cell line, the nature 
of the cargo, and the conditions of incubation. As described above, linear CPPs pass 
through the plasma membrane mostly via an energy-independent or endocytosis pathway.  
Moreover, the cellular delivery of CPP-conjugated molecules also occurs through 
endosomal pathway and a strong enzymatic degradation and an inadequate cytoplasmic 
release of intact molecules from the conjugates are expected, thus leading to an 
inefficient transfer into the cytoplasm. The best strategy to overcome this issue is to 
designing CPP that by pass the endosomal uptake or by increasing the escape rate from 
the endosome to improve the intracellular delivery of CPP-attached molecules. 
 Parang laboratory has reported the cellular uptake of a number of cyclic peptides 
independent of endocytotic pathway. The extraordinary ability of cyclic peptides 
containing tryptophan and arginine, [WR]4 and [WR]5  to spontaneously translocate 
across bilayers independent of an energy source is distinctly different from the behavior 
of the well-known, highly cationic CPPs, such as TAT and Arg9, which do not translocate 
across phospholipid bilayers, and enter cells mostly by active endocytosis.  
Alternatively, researchers have found that an effective cellular delivery vector can 
be improved developed by conjugating a CPP with a fatty acid chain. Amphiphilic 
peptides have also become a subject of major interest as potent antibacterial agents. 
Antimicrobial peptides (AMPs) are produced naturally by bacteria and are considered as 
the first line of host defense protecting against microbial infection. Various types of 
AMPs have been discovered, such as defensins, cecropins, magainins and cathelicidins, 
with significant different structures and bioactivity profiles.  
  
These peptides are reported to be effectors and regulators of the innate immune 
system by increasing production and release of chemokines, and enhance wound healing 
and angiogenesis. They are able to suppress biofilm formation and induce the dissolution 
of existing biofilms. Thus, design of new AMPs with higher activity are urgently needed. 
Although a number of cyclic peptides were discovered and reported as efficient 
cellular delivery agents and/or antimicrobial agents, a more systematic investigation is 
required to identify design rules for optimal entrapment, drug loading, and stability. 
 The balance of many small forces determines the overall morphology, size, and 
functionality of the structures. A deeper understanding of these factors is required for 
guiding future research, and for customizing cyclic peptides for drug loading and cellular 
delivery applications.  
Thus, additional amphiphilic cyclic and linear peptides with variable electrostatic 
and hydrophobic residues were designed here to optimize drug encapsulation. The 
diversity in ring size, amino acid number, position and sequences, number of rings, net 
charge, and hydrophobicity of side chains in cyclic peptides will allow us to explore 
requirements for generating peptides with optimized drug encapsulation and to establish 
correlations between the structure of peptides with their drug entrapment properties. 
Thus, the general objective of this dissertation was to design and evaluate additional 
cyclic or amphiphilic peptides as nanostructures and to compare their efficiency in 
delivery of small molecules with the previously reported cyclic peptides containing 
tryptophan and arginine residues. This dissertation consists of three chapters. 
  
  
 Chapter 1. MANUSCRIPT І (published in Current Organic Chemistry 2014). 
The objective of this work was to design amphiphilic linear and cyclic peptides 
containing hydrophobic tryptophan W residues that were linked through a triazole ring to 
positively charged arginine (R) and lysine (K) residues. The peptides were synthesized 
through click chemistry between hydrophobic peptides containing alkyne and positively 
charged peptides containing azide groups. Their structures were investigated using 
solubility tests, circular dichorism (CD), and transmission electron microscopy (TEM), 
cytotoxicity assays. The conjugates showed minimal cytotoxicity in two cell lines. The 
secondary structures of both peptides were similar to a distorted α-helix as shown by CD 
spectroscopy. TEM imaging also showed that linear-linear (WG(triazole-KR-NH2))3 and 
cyclic-linear [WG(triazole-KR-NH2)]3 peptides formed nano-sized structures.  
 Chapter 2. MANUSCRIPT ІI (Submitted to Journal of Molecular Modeling). In 
this work, we investigated the structural and dynamical aspects of cyclic-linear peptide 
([WG(triazole-KR-NH2)]3 and linear-linear peptide (WG(triazole-KR-NH2))3) formed 
nanostructures compared to a drug delivery system with [WR]4. While [WR]4 was found 
to be an efficient molecular transporter for small molecule drugs, such as lamivudine and 
dasatinib, cyclic-linear peptide ([WG(triazole-KR-NH2)]3 was inefficient. Molecular 
modeling was used to explain the differential behavior of these peptides. We showed how 
the morphology of these systems can affect the drug delivery efficiency. The result of this 
work provided insights about optimizing the amphiphilic cyclic-linear trizaolyl peptides 
with more efficient drug delivery capabilities.    
 Chapter 3. MANUSCRIPT ІII. The objective of this Chapter was to synthesize a 
different series of amphiphilic peptides for different objectives. First, the amphiphilic 
  
trizaolyl peptides in Chapter I were systematically modified by increasing the number of 
arginine and tryptophan sequence in cyclic and linear peptides. The rationale for the 
modification was to enhance the possibility of interaction with the cell membrane and 
therefore improving the cellular uptake process. Moreover, a new class of amphiphilic 
peptides consisting of tryptophan and glutamic acid were conjugated with a peptide 
containing arginine and lysine residues using Fmoc-based peptide chemistry. These 
peptides have an amide bond that generates more flexibility compared to a triazole ring. 
Finally, additional fatty acids with different length chains were conjugated with 
positively charged peptides and evaluated as antibacterial agents. Stearic acid (C16) and 
myristic acid (C14) were conjugated with peptides consisting of arginine azide and lysine 
amino acids to enhance the antibacterial activity. 
In summary, the work in this dissertation provided insights about the synthesis 
and characterization of a new class of amphiphilic triazolyl peptides as drug delivery 
carriers and amphiphilic peptides as antibacterial agents. Molecular modeling was used to 
explain why triazolyl peptides were unable to enhance the delivery of small molecule 
drugs compared to the previously synthesized cyclic peptides [WR]4 (Chapter 2)  
Modification of synthesized peptides in Chapter 1, by addition of more positively 
charged amino acids or reducing the rigidity by incorporating amide bonds instead of 
triazolyl groups can be used to improve the cell penetrating properties. Finally, we 
conjugated amphiphilic peptides with different fatty acids (Chapter 3) to investigate their 
application as antibacterial agents. 
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PREFACE 
 
 This dissertation is written based on the University of Rhode Island “Guidelines 
for the Format of Thesis and Dissertations” standards for Manuscript format. This 
dissertation is composed of three Chapters to satisfy the requirements of the department 
of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode 
Island.  
 
CHAPTER 1:  MANUSCRIPT І:  Amphiphilic Triazolyl Peptides: Synthesis 
and Evaluation as Nanostructure.    
 This manuscript was published in “Current Organic Chemistry”, 2014, 18, 2665 
2671” 
                        
CHAPTER 2:  MANUSCRIPT II:  Cyclic Peptide Nanostructures as Drug  
                   Delivery Systems: Structural Insights and Dynamical Behavior. 
This manuscript was submitted to “Journal of Molecular Modeling”. 
 
CHAPTER 3:  MANUSCRIPT III. Synthesis of Derivatives Amphiphilic Peptides. 
 This manuscript is in process.  
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Abstract 
 
A new class of amphiphilic triazolyl peptides were designed and synthesized from 
peptide-based building blocks containing alkyne and azide functional groups namely 
linear (W(pG))3, cyclic[W(pG)]3, and Ac-K(N3)R-NH2, where W, R, K, and pG represent 
tryptophan, arginine, lysine, and propargylglycine residues, respectively. The linear 
(W(pG))3 and cyclic [W(pG)]3 peptides containing alkyne residues were conjugated with 
Ac-K(N3)R-NH2 functionalized with azide group through click chemistry in the presence 
of CuSO4.5H2O, Cu (powder), sodium ascorbate, and N,N-disopropylethylamine in 
methanol:water to afford amphiphilic triazolyl linear-linear (WG(triazole-KR-NH2))3 and 
cyclic-linear [WG(triazole-KR-NH2)]3 peptides, respectively. The secondary structures of 
both peptides were similar to a distorted α-helix as shown by CD spectroscopy. TEM 
imaging showed that linear-linear (WG(triazole-KR-NH2))3 and cyclic-linear 
[WG(triazole-KR-NH2)]3 peptides formed nano-sized structures in the size range of 50-
100 nm and 50-80 nm, respectively. 
  
Keywords: Amphiphiles, Click chemistry, Cyclic peptides, Nanoparticles, Peptides, 
Triazole. 
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1. Introduction 
 
 Design and synthesis of well-defined materials in nano-sized structures have 
turned into an important field in biomaterials science and biomedicine.
1,2  
Different intra 
and intermolecular forces, such as electrostatic interaction, hydrogen bonding, 
hydrophobic forces, and aromatic stacking contribute to the formation of organized 
structures.
3-5
  
 Peptides have become a subject of major interest because of their unparalleled 
potential applications as nanomaterials, surfactants, and drug delivery systems.
6-8
 Linear 
and cyclic peptides containing appropriate amino acids have been shown to undergo self-
assembly and generate nanostructures.
9
 The generation of self-assembled peptides and 
nanostructures occur through various types of interactions between functional groups of 
amino acid residues, such as electrostatic, hydrophobic, and hydrogen bonding. 
Appropriate design and functionalization of peptides are critical for generating 
nanostructures.  
 Peptides are divided into two major groups namely linear and cyclic. Linear 
peptides adopt higher flexibility in a solution compared to their cyclic counterparts. 
Moreover, peptide cyclization has been used as an effective strategy to decrease the 
conformational freedom of the peptides and to improve the stability against different 
proteolytic enzymes, such as trypsin, α-chymotrypsin, and dipeptidyl-peptidase IV.10 It 
has been previously shown that linear peptides containing hydrophilic and hydrophobic 
amino acids could act as membrane protein stabilizers.
11  
 
 4 
 
 
However, cyclic peptides containing hydrophilic and hydrophobic amino acids 
have shown greater potential as stabilizing agents due to their enhanced chemical and 
enzymatic stability.
12 
The self-assembly of peptides has drawn significant attention 
because of their simple structures and their ability to incorporate multiple inter- and 
intramolecular forces.
13
 Depending
 
on the desired application, various properties 
including polarity, hydrophobicity, and charge in the structure of peptides can be 
manipulated by using different numbers of amino acids to find an optimized balance 
among different forces for self-assembly. Furthermore, the biocompatibility and low 
toxicity of peptides have made them attractive tools in biomedical investigations.
14 
Thus, 
self-assembled peptide nanostructures have employed as biomaterials,
15
 drug delivery 
systems,
16
 protein stabilizers,
17
 and antimicrobial agents.
18 
 
 We have previously reported design and synthesis of linear and cyclic peptides 
containing different L-amino acids with hydrophobic (e.g., W, F, L) and charged residues 
(e.g., K, R, E) by using 9-fluorenylmethyloxycarbonyl (Fmoc)-based peptide chemistry. 
Among all the designed peptides, [WR]4 containing alternative tryptophan and arginine 
residues generated self-assembled nanostructures at room temperature after a specific 
incubation time through hydrophobic force, hydrogen bonding, and/or the π-π stacking 
interactions between tryptophan residues.
6  
A combination of arginine and tryptophan in 
the structure of cyclic peptides was also found to be an optimal sequence for drug 
delivery applications.
7,8
 Moreover, the cyclic nature of peptides was critical in their 
biological activities. For example, cyclic peptides with arginine and tryptophan residues 
exhibited higher potency in kinase inhibition compared to their linear counterparts.
19 
 
 5 
 
 Additional studies are required to investigate sequence effects on morphologies, 
and elucidate the fundamental physical interactions that drive their self-assembly in this 
class of peptides. In
 
continuation of our efforts to explore amphiphilic peptides containing 
tryptophan and arginine residues as nanostructures, herein we report a novel class of 
amphiphilic triazolyl peptides containing tryptophan-based cyclic and linear peptides 
linked through a triazole to positively charged linear peptides. Click chemistry was used 
to attach the cyclic and linear building block peptides containing alkyne with linear 
peptides functionalized with azide residues to generate cyclic-linear or linear-linear 
clicked products. 
 
2. Experimental Section  
General 
 Reactions were carried out in Bio-Rad polypropylene columns by shaking and 
mixing in Glass-Col small tube rotator under dry conditions at room temperature. 
Peptides were synthesized by solid-phase synthesis using N-(9-fluorenyl) 
methoxycarbonyl (Fmoc)-based chemistry and employing Fmoc-L-amino acid building 
blocks. H-Trp(Boc)-2-chlorotrityl resin and/or Rink amide resin were used for the 
synthesis of cyclic and linear peptides, respectively. For the coupling of amino acids, 
Fmoc-Trp(Boc)-OH and Fmoc-L-propargylglycine were used alternatively, 2-(1H-
Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and N,N-
diisopropylethylamine (DIPEA) in N,N-dimethylformamide (DMF) were used as 
coupling and activating reagents, respectively.  
 
 6 
 
 Rink amide resin, H-Trp(Boc)-2-chlorotrityl resin, coupling reagents, and Fmoc-
amino acid building blocks were purchased from Chempep (Miami, FL). Other chemicals 
and reagents were purchased from Sigma-Aldrich Chemical Co. (Milwaukee, WI). Fmoc 
deprotection at each step was carried out using piperidine in DMF (20% v/v). The crude 
peptides were purified by using a reversed-phase Hitachi HPLC (L-2455) on a Gemini 
C18 column (250 mm × 21.20 cm, 10 µm) and a gradient system. The peptides were 
separated by eluting the crude peptides at 10.0 mL/min using a gradient of 0-100% 
acetonitrile (0.1% trifluoroacetic acid (TFA)) and water (0.1% TFA) over 60 min, and 
then were lyophilized. 
The purity of final products (95%) was confirmed by analytical HPLC. The 
chemical structures of the building block peptides and final products were confirmed by 
high-resolution MALDI AXIMA performance TOF/TOF mass spectrometer (Shimadzu 
Biotech) or a high-resolution Biosystems QStar Elite time-of-flight electrospray mass 
spectrometer. 
 
Synthesis of Linear Peptide (W(pG))3 
 The linear peptide was assembled on Rink amide resin (0.59 g, 0.4 mmol, 0.68 
mmol/g) by solid-phase Fmoc/tBu peptide synthesis strategy using Fmoc-protected 
amino acids [Fmoc-Trp(Boc)-OH and Fmoc-L-Propargylglycine] (Scheme 1). The linear 
peptide sequence was assembled on the resin after removing the Fmoc group at the N-
terminal in the presence of 20% piperidine in DMF (v/v) to obtain the sequence NH2-
(pG)W(Boc)(pG)W(Boc)(pG)W(Boc)-Rink amide resin.  
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 The resin was washed with DMF (3 times, 15 mL) and DCM (3 × 15 mL) to 
remove any traces of piperdine. The peptidyl resin was dried in vacuum for 24 h. A 
freshly prepared reagent R cleavage cocktail trifluoroacetic acid 
(TFA)/thioanisole/ethandithol (EDT)/anisole (90:5:3:2, v/v/v/v, 15 mL) was added to the 
resin, and the resin was agitated at room tempertuare for 2 h. The resin was collected by 
filtration and consequently washed with 2 mL of reagent R. The crude peptide was 
precipitated by adding peptide filterates to cold diethyl ether (200 mL, Et2O) and 
centrifuged at 4000 rpm for 5 min followed by decantation to obtain the solid precipitate. 
The solid material was further washed with cold ether (2 × 100 mL). The peptide was 
lyophilized and purified by reversed-phase Hitachi HPLC using a gradient system as 
described above to yield solid white coloured linear peptide (W(pG))3. MALDI-TOF 
(m/z) [C48H47N9O7]: calcd, 860.3758; found, 884.3489 [M + Na + H]
+
.  
 
Synthesis of Cyclic Peptide [W(pG)]3 
 The linear protected peptide sequence was assembled using H-Trp(Boc)-2-
chlorotrityl resin (0.51 g, 0.4 mmol, 0.78 mmol/g). The resin was swelled using DMF (3 
× 30 mL, 10 min) followed by coupling with appropriate amino acids (Fmoc-Trp(Boc)-
OH and Fmoc-L-propargylglycine) and deprotection cycle with piperidine in DMF (20% 
v/v).  The final N-terminal Fmoc group was removed to assemble the sequence on the 
peptidyl resin, NH2-(pG)W(Boc)(pG)W(Boc)(pG)W(Boc)-2-chlorotrityl resin (Scheme 
2). The resin was washed with DMF (3 × 15 mL) and DCM (3 × 15 mL) to remove any 
traces of piperdine. Side chain-protected peptides were cleaved from the resins by 
agitating the peptidyl resin with cleavage cocktail, acetic acid/ 2,2,2-trifluoroethanol 
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(TFE)/dichloromethane (1:2:7, v/v/v, 50 mL) for 1 h at room temperature followed by 
filtration and washing the resin with TFE:DCM (2:8 v/v, 20 mL).  
 The collected filtrate was evaporated to reduce volume residue. Hexane (2 × 25 
mL) and DCM (1 × 25 mL) were added to the residue to remove the acetic acid from the 
residue. The solvents were evaporated to yield a fluffy white solid compound that was 
dried overnight. The cyclization of the protected crude solid peptide was carried out in 
the presence of a mixture of coupling reagents, 1-hydroxy-7-azabenzotriazole (HOAt) 
(162 mg, 0.4 mmol) and N,N-diisopropylcarbodiimide (DIC) (310 µL, 0.4 mmol) in 
anhydrous DMF:DCM (60/200 mL) for 24 h. 
  The solvent was evaporated from a sample solution (5 mL) under reduced 
pressure, and the residue was cleaved with reagent R that confirmed the cyclization by 
mass spectrometry. Thus, all the solvents were removed under reduced pressure that 
generated a high viscous liquid. The final peptide cleavage to remove the side chain 
protection was carried out by shaking the residue with cleavage cocktail, reagent R, 
TFA/thioanisole/anisole/EDT (90:5:2:3 v/v/v/v, 15 mL) for 2 h at room tempertuare. The 
crude peptide was precipitated by the addition of cold diethyl ether (200 mL, Et2O) and 
centrifuged at 4000 rpm for 5 min followed by decantation to obtain the solid precipitate. 
The solid material was further washed with cold ether (2 × 100 mL). The crude peptide 
was lyophilized and purified by reversed-phase Hitachi HPLC (L-2455) as described 
above to yield cyclic peptide [W(pG)]3. MALDI-TOF (m/z) [C48H45N9O6]: calcd, 
843.3493; found 866.2380 [M + Na]
+
. 
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Synthesis of Azide Functionalised Positively Charged Peptide (Ac-K(N3)R-NH2) 
 The peptide was assembled on Rink amide resin (294 mg, 0.2 mmol, 0.68 
mmol/g) by solid-phase peptide synthesis using Fmoc-protected amino acids, Fmoc-
Arg(Pbf)-OH and Fmoc-Lys(N3)-OH. The Rink amide resin was swelled with DCM (50 
mL, 10 min) and then DMF (50 mL, 2 × 10 min). The Fmoc group on the resin was 
deprotected by piperidine in DMF (20%, v/v, 25 mL, 2 × 10 min) followed by washing 
with DMF (3 × 30mL). Fmoc-Arg (pbf)-OH (389 mg, 0.2 mmol/g) was then coupled to 
the peptidyl resin in the presence of coupling reagents HBTU (228 mg, 0.2 mmol/g) and 
DIPEA (210 µL) in N,N-dimethylformamide (DMF, 10 mL). The mixture was agitated at 
room tempertuare for 1 h. The resin was then washed with DMF (3 × 10 mL) for 5 min. 
The Fmoc group was deprotected using using piperidine in DMF (20% v/v, 25 mL, 2 × 
10 min) followed by washing with DMF (3 × 20 mL). The Fmoc-Lys (N3)-OH (173 mg, 
0.2 mmol) was coupled by using HBTU (228 mg, 0.2 mmol), DIPEA (210 µL) in DMF 
for 1 h. The resin was washed with DMF (3 × 20 mL), and Fmoc group was deprotected 
by using piperdine in DMF (20% v/v, 25 mL, 2 × 10 min). The resin was washed with 
DMF followed by capping the amino group by acetic anhdyride (Ac2O, 95 µL, 1 mmol) 
and DIPEA (174 µL, 1 mmol) in anhydrous DMF (3 mL) for 30 min. The resin was 
washed with DMF (3 × 30 mL), DCM (3 × 30 mL), and was dried in vaccum overnight 
before the final cleavage. A freshly prepared cleavage cocktail, TFA /triisopropylsilane 
/water (95:2.5:2.5 v/v/v, 10 mL) was added to the resin and shaken at room temperature 
for 1.5 h. The resin was filtered and evaporated to reduce the volume under dry nitrogen. 
The crude peptide was precipitated by adding cold diethyl ether (200 mL, Et2O) and 
centrifuged at 4000 rpm for 5 min followed by decantation to obtain the solid precipitate. 
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 The peptide was purified by reversed-phase Hitachi HPLC using a gradient 
system, and the HPLC fractions were collected, evaporated and lyophilized to obtain dry 
product. ESI-TOF (m/z) [C14H27N9O3]: calcd, 369.2237; found, 370.2144 [M +H]
+
.  
 
Synthesis of Amphiphilic Triazolyl Peptides by Click Chemistry of Peptides 
(Linear or Cyclic) with an Azide-Functionalized Positively Charged Linear 
Peptide  
 The click reaction was carried out in 20 mL glass vial with small magnetic stir bar 
by adding the alkyne peptide (linear peptide (7.46 mg, 8.68 µmol) or cyclic peptide (7.25 
mg, 8.68 µmol)), CuSO4.5H2O (6.5 mg, 0.026 mmole), Cu powder (16.5 mg, 0.26 
mmol), sodium ascorbate (51.5 mg, 0.26 mmol), and azide-functionalized peptide, Ac-
K(N3)R-NH2 (10 mg, 0.026 mmol) in methanol:water (2:1, 5 mL) followed by addition of 
DIPEA (9 µL, 0.052 mmol). The mixture was stirred at room temperature for 24-48 h. 
The completion of the reaction was confirmed by MALDI mass spectroscopy. The 
reaction mixture was filtered, and the solvent was evaporated under reduced pressure to 
afford the crude product. The crude product was further purified by HPLC using a 
gradient system as described above, and the HPLC fractions were collected, evaporated 
and lyophilized to obtain solid compounds. Linear-linear (WG(triazole-KR-NH2))3, 
MALDI-TOF (m/z) [C90H128N36O16]: calcd, 1969.0309; found 1970.2032 [M + H]
+
; 
Cyclic-linear [WG(triazole-KR-NH2)]3 MALDI-TOF (m/z) [C90H126N36O15]: calcd, 
1951.0203; found 1951.6645 [M]
+
.  
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Circular Dichroism 
  CD spectra were recorded on a JASCO J-810 spectropolarimeter using 1 mm path 
length cuvettes. The scan speed was 100 nm/min, and spectra were averaged over 8 
scans. All experiments on the samples including cyclic-linear [WG(triazole-KR-NH2)]3 
and linear-linear (WG(triazole-KR-NH2))3 (1 mM, H2O) were tested at room temperature. 
The CD for background reference (H2O) was measured and subtracted from the sample. 
 
Transmission Electron Microscopy (TEM) 
  TEM analyses were conducted in JEOL Transmission Electron Microscope 
(Tokyo, Japan) at an accelerating voltage 80 keV. The stock solution (1 mM) in deionized 
water incubated for 3 days was used for the sample preparation. TEM samples of cyclic-
linear [WG(triazole-KR-NH2)]3 and linear-linear (WG(triazole-KR-NH2))3 were prepared 
by depositing a droplet of 5 μL of 1 mM solution in H2O on a carbon-coated Cu support 
grid of mesh size 300, which was allowed to rest for 2 min. After drop casting of peptide 
solution, the grids were then stained with uranyl acetate (20 mL) for 2 min. Excess stain 
was removed, and the grids were allowed to dry overnight. 
 
Molecular Modeling 
 Cyclic-linear [WG(triazole-KR-NH2)]3 monomer was built using GaussView 
software and completely optimized without any contraints utilizing Gaussian 03 software. 
Charge density was plotted and colored according to electrostatic potential.  
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Dynamic Light Scattering (DLS) 
  Zeta potential measurements were conducted by dynamic light scattering using a 
Malvern Instruments Zetasizer Nano ZS (Worcestershire, UK). The machine was 
calibrated using a 60 nm polystyrene standard. Each sample of (WG(triazole-KR-NH2))3 
and [WG(triazole-KR-NH2)]3 (1 mL, of 1 mM) was loaded into a cell, and the particle 
size and zeta potential were measured simultaneously in triplicate. To determine the size 
distribution, 1 mL samples were placed in PCS1115 glass cuvettes and DLS was 
performed at 25 °C at a backscatter angle of 173 with an equilibration time of 120 s. The 
intensity was based on 11 scans. 
 
Cell Culture 
 Ovarian adenocarcinoma SK-OV-3 and Human Embryonic Kidney 293 cells 
HEK-293T cells obtained from American Type Culture Collection (ATCC no CRL-
11268). Cells were grown on 75 cm
2 
cell culture flasks with EMEM medium, 
supplemented with 10% fetal bovine serum (FBS), and 1% penicillin-streptomycin 
solution (10,000 units of penicillin and 10 mg of streptomycin in 0.9 % NaCl) in a 
humidified atmosphere of 5% CO2, 95% air at 37 ºC. 
 
Cytotoxicity Assay 
  SK-OV-3 and HEK-293T cells were plated overnight in 96-well plates with 
density of 5000 cells per well in 0.1 ml of appropriate medium at 37 ºC prior to the 
experiment. The old medium (EMEM containing FBS (10%)) were replaced by different 
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concentrations of linear R3(WG)3 and cyclic R3[WG]3 peptides (5, 10, 15, 25, 50, 75, 
100, 150 µM) in serum containing medium and incubated for 2 h at 37 °C in a humidified 
atmosphere of 5% CO2. Similar experiments were conducted with linear (WG)3 and 
cyclic [WG]3. Compounds were removed from medium by replacing with fresh medium, 
and the cells were kept in an incubator for another 72 h. The cells without compounds 
were incubated in each experiment as control. After 72 h, 20 µl of MTS was added to the 
cell and incubated for 2 h. The absorbance of the formazan product was calculated with 
the fluorescence intensity at 490 nm using a SpectraMax M2 microplate 
spectrophotometer. The percentage of cell survival was calculated as [(OD value of cells 
treated with the test mixture of compounds) − (OD value of culture medium)]/[(OD value 
of control cells) − (OD value of culture medium)] × 100%. 
 
3. Results and Discussion  
 Click chemistry has been previously used to design diverse structures of peptide 
scaffolds. For instance, different derivatives of a triazole-containing kinase inhibitor 
cyclo-[Pro-Val-Pro-Tyr] peptide were synthesized through click chemistry.
20
 
Furthermore, triazoles were found to be an appropriate substituent for the amide bond in 
peptides with a α-helical structure.21 Horne et al. designed a class of cyclic peptides 
containing 1,4- or 1,5-disubstituted 1,2,3-triazoles
22
 that were found to serve as 
surrogates for trans or cis amide bonds, respectively. Synthesis of amphiphilic peptides 
containing hydrophobic and positively charged residues by click chemistry remains 
unexplored. To the best of our knowledge, this is the first report of amphiphilic cyclic-
linear and linear-linear peptides linked through a triazole spacer.  
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 The synthesis of linear-linear (WG(triazole-KR-NH2))3 and cyclic-linear 
[WG(triazole-KR-NH2)]3 peptides containing triazole rings were performed in two major 
steps by synthesizing the building blocks containing alkyne and azide residues. First, 
linear (W(pG))3 and cyclic [W(pG)]3 building block peptides (where (pG) = 
propargylglycine) containing alkyne residues were synthesized by Fmoc-based chemistry. 
Second, a building block containing azide residue, Ac-K(N3)R-NH2, was synthesized. 
Finally, the building blocks were conjugated with each other through click chemistry. The 
linear peptide (W(pG))3 was assembled on Rink amide resin (0.4 mmol, 0.68 mmol/g) by 
solid-phase Fmoc/tBu peptide synthesis strategy using Fmoc-Trp(Boc)-OH and Fmoc-L-
propargylglycine (Scheme 1).  
 The peptide sequence was assembled on the resin followed by removing of the N-
terminal Fmoc group to obtain the sequence NH2-(pG)W(Boc)(pG)W (Boc)(pG)W(Boc)-
Rink amide resin. The linear peptide was obtained after cleavage of peptidyl resin using 
reagent R cleavage cocktail (trifluoroacetic acid (TFA)/thioanisole/ethanedithiol 
(EDT)/anisole (90:5:3:2, v/v/v/v)) by shaking the mixture at room temperature for 2 h, 
followed by precipitation with cold ether and centrifugation to afford solid crude linear 
(W(pG))3 peptide, which was further purified by using HPLC.  
 In contrast with the synthetic procedure for the linear peptide, the cyclic peptide 
[W(pG)]3 was synthesized by using H-Trp(Boc)-2-chlorotrityl resin (0.4 mmol, 0.78 
mmol/g,) (Scheme 2). The resin was swelled using DMF followed by coupling and 
deprotection cycles using appropriate amino acids and piperidine in DMF (20% v/v). The 
final N-terminal Fmoc group was removed to assemble the sequence on the peptidyl 
resin, NH2-(pG)W(Boc)(pG)W(Boc)(pG)W(Boc)-2-chlorotrityl resin.    
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 The side chain protected peptide was cleaved from the resin by agitating the resin 
with cleavage cocktail, acetic acid/2,2,2-trifluoroethanol (TFE)/dichloromethane (1:2:7, 
v/v/v) for 1 h at room temperature followed by filtration and evaporation of cocktail 
liquid to afford the crude side chain protected peptide. The peptide was dried overnight 
followed by N- to C-terminal cyclization by using coupling reagents, 1-hydroxy-7-
azabenzotriazole (HOAt) and N,N′-diisopropylcarbodiimide (DIC) in DMF/DCM under 
diluted conditions for overnight. The progress of the reaction was monitored by using 
MALDI-TOF. The solvent was evaporated and Boc protecting groups were removed in 
the presence of reagent R cleavage cocktail for 2 h followed by precipitation and HPLC 
purification to afford the cyclic peptide.  
 The synthesis of azide-functionalized positively charged peptide building block 
(Ac-K(N3)R-NH2) was performed on Rink amide resin (0.2 mmol, 0.68 mmol/g) using 
building blocks of Fmoc-protected amino acids including Fmoc-Arg(pbf)-OH and Fmoc-
Lys(N3)-OH. The resin was swelled and deprotected to couple arginine followed by 
deprotection and coupling with Fmoc-Lys(N3)-OH. The Fmoc group was deprotected, 
and amino group was further capped using acetic anhydride in DMF. The peptide was 
cleaved from the resin using a cleavage cocktail containing TFA/TIS/H2O (95:2.5:2.5, 
v/v/v) and purified by HPLC to afford Ac-K(N3)R-NH2 (Scheme 3).  
 Finally, the linear-linear and cyclic-linear amphiphilic triazolyl peptides were 
synthesized by click reaction between the linear or cyclic peptides containing alkyne, 
(W(pG))3 and [W(pG)]3, and azide-functionalized linear peptide Ac-K(N3)R-NH2 in 
solution phase using CuSO4
.
5H2O, Cu powder, sodium ascorbate, and N,N-
diisopropylethylamine (DIPEA) in methanol/water for 24-48 h (Scheme 4).  
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 The azide peptide Ac-K(N3)R-NH2 was used in excess (more than 3 equiv) to 
conjugate with the three alkyne functional groups in the linear or cyclic peptides at room 
temperature and afford the linear-linear (WG(triazole-KR-NH2))3 and cyclic-linear 
[WG(triazole-KR-NH2)]3 in 33-35% yield (Scheme 5). The formation of the conjugated 
1,4 product was confirmed by MALDI-TOF mass spectroscopy. The structure of 
optimized conformation of cyclic-linear [WG(triazole-KR-NH2)]3 monomer was 
evaluated for charge distribution. The modeling exhibited positively charged arginine 
extending out of the cyclic peptide (Figure 1). The secondary structure of peptides is one 
of the responsible elements in the self-assembly pattern.  
 Circular dichroism (CD) was employed to obtain insights about the secondary 
structure of both peptides. The secondary structures of the majority of peptides are 
divided into three major classic forms namely β-sheet, α-helix, and random coil. The β-
sheet structures get stabilized through available hydrogen bonding between oligopeptide 
strands. However, intra-chain hydrogen bonds help the α-helix to form a stable coiled 
structure. The CD results showed that both peptides have a relatively similar structure. 
CD spectra of the cyclic-linear peptide (1 mM) solution in water at room temperature 
showed two minima peaks at 226 nm and 199 nm. The linear peptide exhibited a similar 
CD pattern to the cyclic peptidewith two minima peaks at 226 nm and 202 nm (Figure 2). 
However, a blue shift from 202 to 199 nm was found for the cyclic peptide as compared 
to the linear, suggesting that the secondary structure of the cyclic peptide is slightly 
different. A distinct α-helix structure shows two minima peaks at 222 and 208 nm. Thus, 
the structures of these peptides did not follow a typical α-helical structure. 
 
 17 
 
 The size and morphologies of peptide nanoparticles were monitored by using 
transmission electron microscopy (TEM). As shown in Figure 3, the cyclic-linear 
[WG(triazole-KR-NH2)]3 formed spherical nanostructures in the size range of 50-80 nm. 
However, the linear-linear (WG(triazole-KR-NH2))3 exhibited entirely different 
morphologies and size compared to that of the cyclic-linear counterpart. The linear 
peptide showed nanosized network with particles as small as 5-10 nm. Small sized 
particles showed aggregation by forming larger particles in the size range 50-100 nm 
(Figure 4). DLS studies showed a monodisperse size distribution for both linear-linear 
(WG(triazole-KR-NH2))3 and cyclic-linear [WG(triazole-KR-NH2)]3 while the latter 
showed larger nanoparticles (Figures 5 and 6). 
 Although linear-linear and cyclic-linear peptides share the equal number of 
similar amino acids, they form different types of particles presumably because of the 
difference in the orientation of positively charged guanidine groups in arginine and 
hydrophobic tryptophan residues.  
Cytotoxicity of both linear-linear (WG(triazole-KR-NH2))3 and cyclic-linear 
[WG(triazole-KR-NH2)]3 peptides were evaluated in SK-OV-3 and HEK-293T cells 
(Figures 7 and 8). In general, the peptides did not show significant toxicity at 
concentration of <25 µM in HEK-293T cells. While cyclic-linear [WG(triazole-KR-
NH2)]3 did not exhibit any significant toxicity in SK-OV-3 cells at a concentration of 75 
µM, linear-linear (WG(triazole-KR-NH2))3 reduced the cell proliferation by 20% at this 
concentration. Similar results were obtained when comparing linear (W(pG))3 (Figure 9) 
and cyclic [W(pG)]3 (Figure 10) building blocks, showing the cyclic peptide less 
cytotoxic than the linear counterpart. 
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4. Conclusion 
 In conclusion, a new class of amphiphilic peptides containing arginine and 
tryptophan, linear-linear (WG(triazole-KR-NH2))3 and cyclic-linear [WG(triazole-KR-
NH2)]3, was synthesized by using click chemistry. CD spectroscopy exhibited that the 
secondary structures of both peptides have a similar pattern. Cyclic-linear [WG]3 and 
linear-linear (WG)3 showed nano-sized structures in a range size of 50-100 nm. 
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Figure Legends: 
 
Figure 1. Molecular electrostatic potential surface of [WG(triazole-KR-NH2)]3.  
Figure 2. CD spectra of linear-linear (WG(triazole-KR-NH2))3 and cyclic-linear 
[WG(triazole-KR-NH2)]3.   
Figure 3. TEM images of cyclic-linear [WG(triazole-KR-NH2)]3. 
Figure 4. TEM images of linear-linear (WG(triazole-KR-NH2))3. 
Figure 5. Dynamic light scattering (DLS) of linear-linear (WG(triazole-KR-NH2))3.  
Figure 6. Dynamic light scattering (DLS) of cyclic-linear [WG(triazole-KR-NH2)]3. 
Figure 7. Cytotoxicity of linear-linear (WG(triazole-KR-NH2))3 and cyclic-linear 
[WG(triazole-KR-NH2)]3 in HEK-293T cells after 2 h.  
Figure 8. Cytotoxicity of linear-linear (WG(triazole-KR-NH2))3 and cyclic-linear 
[WG(triazole-KR-NH2)]3 in SK-OV-3 cells after 2 h.  
Figure 9. Cytotoxicity of linear (WG)3 in SK-OV-3 cells after 2 h. 
Figure 10. Cytotoxicity of cyclic [WG]3 in SK-OV-3 cells after 2 h. 
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Figure 8.  
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Figure 9.  
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Figure 10.  
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Scheme Legends: 
Scheme 1. Synthesis of linear (W(pG))3 as the building block. 
Scheme 2. Synthesis of cyclic [W(pG)]3 as the building block. 
Scheme 3. Synthesis of positively charged peptide containing azide as the building 
block. 
Scheme  4. Synthesis of linear- linear (WG(triazole-KR-NH2))3 and cyclic-linear 
[WG(triazole-KR-NH2)]3.  
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Ab initio molecular orbital calculations 
alongwith molecular dynamics simulations 
and experimental results are reported for 
nanostructure formation by amphiphilic 
peptides suitable for                         
enhancing drug delivery. It was shown that 
conformational flexibility, charge 
environment, and hydrophilicity-
lipophilicity balance of these peptides play 
important roles in determining the 
nanostructure and its suitability for drug 
transportation across cell membrane. 
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Abstract 
The objective of this study was to understand the differential behavior of nanostructures 
formed by cyclic peptides containing tryptophan and arginine residues at the molecular 
level. [WR]4 was reported to be effective in enhancing cellular delivery of a number of 
drugs, such as lamivudine (2′,3′-dideoxy-3′-thiacytidine, 3TC) and dasatinib while 
[WG(triazole-KR-NH2)]3 was found to be an inefficient molecular transporter. Ab initio 
molecular orbital calculations coupled with molecular dynamics simulation studies along 
with experimental results showed that nanostructure formation by these cyclic peptides 
were induced by counterions. Our results showed the suitability of [WR]4 system in 
enhancing the delivery of fluorescence-labeled drugs (e.g., fluorescence-labeled 3TC (F′-
3TC) and fluorescence-labeled daststinib (F′-Das)) were consistent with the experimental 
results. The conformational flexibility, charge environment, and hydrophilic-lipophilic 
balance (HLB) of these peptides were found to play important roles in determining their 
drug delivery capabilities.                
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Introduction 
 
 Bioorganic peptide nanostructure refers to a synthetic peptide molecule that can 
spontaneously self-assemble to form structures of diameter up to 50 nm. Such self-
assembled structures have drawn the attention of scientists in diverse fields due to 
attractive applications in medicine, material science, biotechnology, and nanotechnology 
based devices.
1-6
 These self-assembled structures are largely held together by non-
covalent interactions like hydrogen bonding, electrostatic interactions, and hydrophobic 
interactions.
7-9 
Self-assembling systems have conventionally been of interest to scientists 
requiring different types of ecofriendly biosurfactants for membrane stabilization.  
Peptides surfactants, or pepfactants, have emerged as interesting alternatives 
forming dynamic nanostructures in pure solution. Cyclic peptides with amphiphilic 
groups are more stable as compared to their linear counterparts but have remained less 
studied due to their synthetic complexities.
10 
We have recently reported on some 
amphiphilic cyclic L-peptides forming spontaneous nanostructures acting as stabilizing 
agents for silver nanoparticles and proteins.
11
 Self-aggregation of biosurfactants in the 
bulk aqueous phase forms different shapes like spherical, bilayer, or cylindrical 
depending on hydrophilic-lipophilic balance (HLB). It is known that short amphiphilic 
peptides containing 10–30 amino acid residues (mostly cationic residues like arginine or 
lysine) possess the ability to penetrate the cell membrane.
12-15
 These cell-penetrating 
peptides (also referred to as CPPs) have been successfully utilized to deliver a large 
number of macromolecules like proteins, oligonucleotides, and polysaccharides 
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intracellularly without causing significant toxicity.
16-25 
 CPPs can exert their effect in 
vitro and in vivo in micromolar concentrations.
26
  
We have reported 27-fold enhancement in the cellular uptake of fluorescence-
labelled phosphopeptide F'-PEpYLGLD in presence of 50 µΜ solution of cyclic peptide 
[WR]4 (Figure 1) containing tryptophan and arginine residues.
27 
Isothermal calorimetry 
studies confirmed the interaction between the cyclic peptide carrier and the negatively 
charged cargo phosphopeptides. We have recently designed and reported amphiphilic 
triazolyl peptides (Scheme 1) synthesized from peptide building blocks containing alkyne 
and azide functional groups. Cyclic [W(pG)]3 (containing alkyne) (where (pG) = 
propargylglycine) was conjugated with a peptide functionalized with azide group, Ac-
K(N3)R-NH2, through click chemistry to afford cyclic-linear [WG(triazole-KR-NH2)]3 
peptide (Figure 1).
28  
The resulting cyclic-linear peptide formed nanostructures and was 
compared as a drug delivery system with [WR]4. 
In the present work, we report on the structural and dynamical aspects of these 
nanostructures and how these properties govern their drug delivery capabilities. We 
investigated how the morphology of these systems can be tuned to attain desired 
nanostructures with desired drug delivery capabilities. Ab initio molecular orbital 
calculations were used in conjunction with intermolecular interaction studies and 
molecular dynamics simulations. 
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Methods 
Ab initio molecular orbital calculations 
29,
 with complete geometry optimizations, 
were performed at the Hartree Fock level utilizing CEP-31G 
30 
basis set for the monomer 
cyclic peptides. Geometry optimizations were performed utilizing Berny’s gradient 
method.
31,32
  Self-assembly was explored step by step to determine the possibility of 
dimer formation, trimer, tetramer, respectively, by repeated interaction energy 
calculations. Every time a monomer is added interaction energy was calculated as 
                                        Interaction energy = Ecomplex of n monomers – (n. Emonomer) 
In this case since the monomers are cationic and repel each other in the absence of 
counterions, this is the energy consumed in nanoparticulate formation in the absence of 
counter ions. In the presence of counter ions, energy released in nanoparticulate 
formation is given as                                                                 
Interaction energy = Ecomplex of n monomers and m counterions – (n. Emonomer + m Ecounterion)                                                                                 
Different possibilities of self-assembly were considered, such as tubular, film 
formation, and spherical nanoparticulate formation in presence and absence of 
counterions. Self-aggregation and nanostructure formation were considered in the 
presence of inducing trifluoroacetate counterions present under experimental conditions. 
Trifluoroacetic acid (TFA) (2%) was added to water and acetonitrile for HPLC 
purification.  
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These calculations were carried out using GAUSSIAN ’0933 software and 
GAUSSVIEW
34
 was used for viewing purposes.  After nanostructure formation, its role 
as drug delivery system was investigated through molecular dynamics simulations. First 
the cargo drug was docked inside the nanostructure manually. The stability of this loaded 
nanostructure with time and its dynamical behavior were then studied utilizing molecular 
dynamics simulation. The containment of drug for a period followed by its delivery was 
also studied through simulations.  
The self-aggregated nanostructure in presence of counterions with drug loaded in 
core was subjected to relaxation prior to molecular dynamics simulations. System was 
then subjected to simulated annealing followed by long dynamics at 300K. Shaw’s 
Desmond software
35,
 was utilized for the purpose using OPLS force field.
36
 NPT 
(isothermal-isobaric) ensemble was taken using Martyna-Tobias-Klein barostat method.
37
 
Reversible reference system propagator algorithms (RESPA integrator) was used with 2 
fs time step for near and bonded atoms and 6 fs time step for far atoms.
38
  Coulombic 
interaction cutoff was set at 9.0 A. 3.0 ns trajectory was evaluated in each case. Energy 
analysis and RMSD analysis for all heavy atoms are presented to judge the stability of the 
system with time. RMSD was taken with reference to frame zero after relaxation of the 
system. 
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Cell-based Assays 
Cell Culture 
Human leukemia cells (CCRF-CEM, ATCC no. CCL-119) were purchased 
obtained from American Type Culture Collection. Cells were cultured in 75 cm
2
 flasks 
containing RPMI-16 medium. The medium contains supplemental, such as fetal bovine 
serum (FBS, 10%) as well as penicillin-streptomycin (penicillin: 1%, 10 000 units and 
streptomycin: 10 mg in 0.9% NaCl) that were used under humidified atmosphere 
balancing CO2 (5%) and air (95%) at 37 °C.  
 
Flow Cytometry Studies 
CCRF-CEM cells (1 × 10
7
/well) were plated in 6-well plates. Fluorescence-
labeled dasatinib (F´-Das) was used as a model drug for this comparative experiment. 
Thus, F´-Das (5 μM) was added alone and in combination with [WR]4
11b  
and 
[WG(triazole-KR-NH2)]3 
28 
 into wells. All experiments were carried out in triplicate. All 
plates were kept at 37 °C for 2 h. In this assay, cells with no treatment with F´-Das were 
employed as negative controls. The treatments were removed after 2 h of incubation. To 
wash the cell membrane surface, trypsin−EDTA solution was used for 5 min. After that, 
the cells were twice washed with PBS (5 min each time). To prepare cells for analysis, 
they were resuspended in flow cytometry buffer and filtered. The analysis of the 
experiment was performed by FACSVerse flow cytometer using FITC channel. The data 
for each entry was acquired based on the signal mean fluorescence in 10,000 cells.  
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All assays were performed in triplicate. A similar procedure was used for flow 
cytometry studies of the fluorescence-labeled 3TC (F′-3TC) in the presence of the 
peptides. 
  
Results and Discussion 
 We have previously shown that peptides containing amino acids with 
hydrophobic and positively charged residues can form nanostructures at room 
temperature.
11 
The presence of optimized balance between hydrophobicity and charge 
was determined to be a major driving force for the formation of self-assembled 
nanostructures through inter and intramolecular interactions.  
 Initial TEM imaging of [WR]4 showed that this peptide forms nano-spherical 
particles with the size of 70-85 nm. Multiple forces could be responsible in forming 
nanosized structure. Hydrophobic segments of the peptide can trigger the supramolecular 
self-assembly and force the peptide to generate nanospherical structures.  Furthermore, 
TEM investigations on size and morphologies of [WG(triazole-KR-NH2)]3 showed that 
this peptide can also form spherical structures in the size range of 50-80 nm in aqueous 
media (Figure 2). Several factors can be involved in the formation of such a structure, 
including hydrogen bonding and hydrophobic forces.
28
 TEM observation revealed that 
although the structure of [WG(triazole-KR-NH2)]3 and [WR]4 are different, they 
generated nanoparticles with similar size range and morphologies. Chemical structure of 
[WG(triazole-KR-NH2)]3 represents a higher degree of flexibility in arginine side chains 
compared to that of [WR]4.  
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 However, existence of triazole rings could also induce some degree of rigidity to 
the structure of [WG(triazole-KR-NH2)]3. These data suggest that the orientation of amino 
acids, such as tryptophan and arginine, can determine the size and morphologies of 
nanostructures. 
 Cyclic peptide containing tryptophan and arginine [WR]4 and the amphiphilic 
triazolyl cyclic-linear peptide [WG(triazole-KR-NH2)]3 were completely optimized 
utilizing ab initio Hartree Fock molecular orbital calculations at the CEP-31G level.  The 
structures of these systems along with their optimized conformations are shown in Figure 
1.  The molecular electrostatic potential surfaces for both systems are shown in Figure 3.  
Both systems are cationic in nature, and the data clearly indicate that they require 
inducing counterions for self-aggregation. However, this became more obvious on a 
detailed examination of the differences in the potential surfaces of both systems. 
  In [WG(triazole-KR-NH2)]3 system, the positive charge is located at the ends of 
the long KR-NH2 side chains; whereas in [WR]4 system the positive charge is delocalized 
over the entire system. Because of these differences, the location of counterions in both 
systems is quite different resulting in a more compact spherical aggregated form in 
[WR]4 that is more stable. The experimental procedure for purification of both peptides 
required the use of trifluoroacetate (TFA). Thus, TFA ions were present as the 
counterions. Considering the availability of these ions, ab initio intermolecular interaction 
calculations were performed to study counterion-induced self-aggregation of these 
systems.  
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 As mentioned earlier, self-aggregation may be in different shapes.  Therefore, we 
examined multiple shapes relevant to explain the behavior of these systems at lipid 
membrane interface and their molecular transporter properties.  Results for self-
aggregation of cyclic peptide [WR]4 and cyclic-linear peptide [WG(triazole-KR-NH2)]3 
are shown in Figures 4 and 5, respectively. Both systems showed formation of spherical 
nanoparticulates suitable for drug carriage and delivery. The linear or tubular stacking 
does not generate an inner core sufficiently large enough for the carriage of drugs or 
molecules. The monomer conformations of cyclic peptides under consideration are not 
appropriate for tubular structure formation. Overall charge neutrality was maintained in 
the aggregated form to enable us to study the dynamical behavior utilizing simulation 
studies. The nanostructure formed by [WR]4 system has the dimensions 7.2 nm x 6.9 nm 
x 2.0 nm while the nanostructure formed by [WG(triazole-KR-NH2)]3 system has the 
dimensions 12.0 nm x 10.6 nm x 3.2 nm. These dimensions may vary with variations in 
aggregated forms but are indicative that the aggregated forms lie in the range of 
nanostructure. 
 To compare the transporting ability of [WG(triazole-KR-NH2)]3 and [WR]4, a 
flow cytometry assay was carried out. Fluorescence-labeled dasatinib (F'-Das) was 
employed as a model molecular cargo. The intracellular uptake of F'-Das was evaluated 
in the presence of [WG(triazole-KR-NH2)]3 and [WR]4 and compared with that of the 
drug alone. As it is shown in Figure 6, the presence of [WR]4 enhanced the cellular 
uptake of F'-Das by 2.5 fold compared to that of F'-Das alone. However, the results 
showed that the intracellular uptake of F'-Das was not enhanced in the presence of 
[WG(triazole-KR-NH2)]3. These data indicated that although both peptides contain 
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tryptophan and arginine amino acids, they have different transporting abilities for the 
delivery of F'-Das due to other factors. 
 Moreover, the intracellular transporting potency of [WR]4 and [WG(triazole-KR-
NH2)]3 were compared by using lamivudine (3TC), an anti-HIV drug. The fluorescence-
labeled 3TC was prepared based on our previously reported procedure.
11  
As expected, 
the flow cytometry results showed that the cellular uptake of F´-3TC (5 µM) was 
increased by more than 3-fold when mixed with [WR]4 (50 µM). However, uptake of F´-
3TC was reduced in the presence of [WG(triazole-KR-NH2)]3. These data confirmed that 
[WR]4 is a molecular transporter while  [WG(triazole-KR-NH2)]3 is inefficient in 
improving the cellular delivery. 
 Molecular modeling and ab intio intermolecular interaction calculation were used 
to explain the differential behavior of these two cyclic peptides as molecular transporters. 
The drugs were loaded inside nanostructure to study their carriage and delivery by the 
peptides. Figures 7 and 8 shows a comparison of solvation energy of fluorescence-labeled 
3TC (F′-3TC) and dasatinib and stabilization of drugs inside the nanostructures formed 
by the two cyclic peptides.  
 The stabilization of drug inside nanostructures clearly indicates why the drug will 
be spontaneously encapsulated by the peptides. Figure 9 shows a comparison of solvation 
energy of fluorescence-labeled dasatinib (F′-Das) and its stabilization inside the 
nanostructures formed by cyclic peptides. In this case, stabilization offered by peptide 
nanostructures indicates spontaneous encapsulation of drug. It is also to be noted that the 
stabilization of drug inside the nanostructure formed by [WG(triazole-KR-NH2)]3 system 
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is lower than that of [WR]4. This is due to overall lower charge on [WG(triazole-KR-
NH2)]3 resulting in less number of counterions and less compact nanostructure due to 
monomer conformation. 
 The stability of encapsulated drug and chances of premature expulsion were 
studied by molecular dynamics simulation studies by evaluating 3ns trajectory. The 
results for carriage of both the drugs by [WR]4 peptide nanostructure are shown in Figure 
10.  Snapshot of system during relaxation and root mean square deviations (RMSD) of all 
heavy atoms throughout simulation are also shown in Figure 10. The RMSD plot clearly 
shows a reduction in mobility of peptide monomers on nanostructure formation with 
trifuoroacetate counterions and after loading nanostructure with F′-3TC as well. 
Encapsulation of F′-Das leads to some instability perhaps due to the larger size of the 
drug. 
Carriage of fluorescence-labeled anti-HIV drug F′-3TC and anticancer drug F′-Das 
by [WG(triazole-KR-NH2)]3 nanostructure are shown in Figure 11.  Snapshots of relaxed 
system during simulation show a very loosely held nanostructure which has opened up to 
some extent depicting probability of premature expulsion of both the drugs.  Moreover, 
noticeable is the significant change in monomer conformations with folded (KR-NH2) 
side chains.  The flexible side chains of this peptide have folded to maximize electrostatic 
interactions with TFA and intramolecular H-bonding as opposed to interactions with the 
drug.  
This is in contrast to the encapsulation of these drugs by [WR]4 nanostructure 
which maximizes interactions with drugs to form a compact loaded nanostructure. The 
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HLB of this system also seems to play a critical role in this reorganization leading to 
loosely held nanostructures inappropriate for drug delivery. RMSD shows little effect of 
drug loading perhaps due to opening of nanostructure and expulsion of the drug at the 
time of relaxation itself during initial stages of the simulation.  
 This study depicts the suitability of cyclic peptide [WR]4 nanostructures in 
enhancing the bioavailability of anti-HIV and anticancer drugs of appropriate size. 
However, cyclic peptides containing cell permeability enhancing arginine residues, but 
with high mobility of side chains are found to be unsuitable for delivery purposes.  
 
Conclusions  
 In this study, we have presented ab initio molecular orbital calculations coupled 
with molecular dynamics simulation studies to show how cyclic amphiphilic peptide 
[WR]4 forms nanostructures by self aggregation induced by counterions and enhances the 
cellular delivery of certain nuclear targeted anticancer agents. We have also shown that in 
[WG(triazole-KR-NH2)]3 the cargo-loaded nanostructures were not stable, leading to 
premature expulsion of the drug and no significant enhancement in cellular delivery. The 
conformational flexibility of cyclic peptides, their charge environment, and HLB ratio all 
play important roles in governing the self-aggregation and molecular transporter 
properties of these amphiphilic cyclic peptides. Molecular dynamics simulation results 
confirm the experimental cellular assay observations. 
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Figure Legends: 
 
Figure 1. TEM images of [WG(triazole-KR-NH2)]3 (a,b) and [WR]4 (c,d). 
Figure 2. Molecular electrostatic potential surfaces of cyclic peptides. 
Figure 3. Self-aggregation of [WR]4. 
Figure 4. Self-aggregation of [WG(triazole-KR-NH2)]3. 
Figure 5. Cellular uptake of F'-Das in the presence of [WR]4 and [WG(triazole-KR-
NH2)]3.  
Figure 6. Cellular uptake of F'-3TC in the presence of [WR]4 and [WG(triazole-KR-
NH2)]3. 
Figure 7. Comparison between stabilization of F′-3TC in aqueous solution and 
stabilization inside peptide nanostructures of [WG(triazole-KR-NH2)]3. 
Figure 8. Comparison between stabilization of fluorescein-labeled dasatinib in 
aqueous solution and stabilization inside peptide [WG(triazole-KR-NH2)]3 
nanostructure. 
Figure 9. Carriage of fluorescein labeled lamivudine by [WR]4 nanostructure.  
Figure 10. Carriage of fluorescein-labeled dasatinib by peptide [WG(triazole-KR-
NH2)]3. 
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Figure 3. 
 
   
 
 
 
 
 
 
Interaction energy= -2806.14 kCal/mol
Interaction energy= -1212.93 kCal/mol
Length ~ 7.2 nm
Breadth ~ 6.9 nm
Height ~2.0 nm
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Figure 4. 
  
 
 
 
 
 
 
 
Interaction energy= -1,470.93 kCal/mol
Interaction energy= -1,648.37 kCal/mol
Length ~ 12.0 nm 
Breadth ~10.6 nm
Height ~ 3.2 nm
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Figure 9. 
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Figure 10. 
   
 
 
 
 
 71 
 
Scheme Legends: 
 
Scheme 1. Structures and optimized conformations of cyclic amphiphilic peptides 
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Abstract 
 
Three classes of amphiphilic peptides were synthesized and evaluated as molecular 
transporters and/or antibacterial agents. Herein we describe the details of the synthesis of 
the compounds using click chemistry or amide conjugation. The three classes include (a) 
cyclic-linear [WG(triazol-KR-NH2)]4 and linear-linear (WG(triazol-KR-NH2))4 
conjugated through a triazolyl linker, (b) cyclic-linear [WG(AC-KR-NH2)]3 and linear-
linear (WE(AC-KR-NH2))3 conjugated through an amide linker, and (c) fatty acyl 
triazolyl peptides containing myristoyl and stearoyl substituents. The syntheses were 
accomplished through solid-phase methods followed by click chemistry or amide 
formation to install the arginine side chains and fatty acyl groups, respectively.  
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Introduction 
 Enhanced translocation of drug compounds across plasma membranes is an 
important strategy to reduce the administered dose and subsequently the side effects of 
drugs. Among the cell-penetrating peptides (CPPs), arginine-rich peptides have been 
studied widely and gained much attention due to their efficiency, simplicity, and aqueous 
solubility.
1
 Cationic residues in CPPs, particularly the guanidine moiety in arginine-rich 
peptides, have been known to play a crucial role for the membrane translocation 
capability.
2,3
  
The critical role of arginine residues in the interaction of CPPs with cell 
membranes has been described previously by systematic replacement of arginine residues 
with alanine residues. Such substitutions induced a strong reduction of peptide uptake 
that was correlated with the number of substituted arginine residues. Thus, the central 
structural scaffold of the peptides required for cellular uptake was the guanidine head 
group of arginine.
4
 Several studies on the binding affinities of cationic cell penetrating 
peptides indicate that CPPs strongly bind electrostatically to the negative charges on the 
cell membranes, including lipid head groups, proteins like nucleolin, and proteoglycans 
such as heparin sulfate.
5,6
 Although electrostatic interactions are known to be important 
for arginine-rich cell-penetrating peptides, non-electrostatic effects such as 
hydrophobicity and peptide structural transitions can also contribute to the binding 
affinity of amphiphilic cell-penetrating peptides to cell membranes.
7
 
 The successful therapeutic strategies using CCPs has been limited by the poor 
delivery efficiency of existing synthesized amphiphilic peptides. The development of 
alternative modified peptides for improved delivery of therapeutic agents and enhanced 
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biological activity is needed urgently.  Parang and coworkers have discovered a new class 
of amphiphilic peptides, namely [WR]4 that showed the ability to translocate across the 
cell membrane. Both the positively charged residues and hydrophobic tryptophan 
contributed in enhancing the cellular uptake property of [WR]4. Fluorescence activated 
cell sorting (FACS) analysis showed that the cellular uptake of F′-PEpYLGLD in the 
presence of [WR]4 was increased by 27-fold when compared to F′-PEpYLGLD alone.
8
 
 Amphiphilic peptides have also become attractive and received attention as  
potential antibacterial agents. Antimicrobial peptides (AMPs) are produced in nature and 
are considered the first line of host defense protecting living organisms from pathogenic 
microorganisms. AMPs are produced at low levels in multi-cellular organisms.
9
  
Synthetic amphiphilic peptides have been shown to possess a broad spectrum of 
antitumor, antiviral, and antifungal activities.
10,11
 The mechanism of action of 
antimicrobial peptides involves a non-receptor mediated mechanism whereby the 
compounds directly target the lipid membrane of the cells.
12
 All AMPs tend to share 
some common characteristics, such as having amphipathic structure containing both 
hydrophilic and hydrophobic residues that allow binding to the hydrophilic and 
hydrophobic core of the membrane.
13
 
AMPs have nonselective binding since they cannot differentiate between 
prokaryotic and eukaryotic cells based on hydrophobicity.
14
 All AMPs consist of high 
number of cationic amino acids that result in net positive charge on the peptides, which 
will bind to the anionic lipids in the bacterial membrane.
15
 It has been reported that 
reducing the positive charge of peptides will lower the activity and subsequently the 
selectivity of AMPs.
16,17
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Parang et al. (2014) recently reported the synthesis of amphiphilic cyclic CPPs, 
such as [R4W4] that exhibited potent activity against methicillin-resistant Staphylococcus 
aureus (MRSA) with a minimum inhibitory concentration (MIC) of 2.67 µg/mL.
18 
It has been previously reported that addition of fatty acids tail connected to the 
AMPs can enhance both the activity and selectivity of the peptides 
19,20
 Matthew and his 
co-workers reported that conjugation of fatty acid to the AMPs led to increased 
antibacterial activity of amphiphilic peptides.
21
 A new class of peptide amphiphilic (PAs) 
containing positive charged peptide conjugated with fatty acyl chains showed significant 
improvement in delivery of different cargo molecules.
22
 Studies on the antimicrobial 
peptide lactoferrin showed that peptide conjugated with twelve carbon fatty acid was able 
to improve the activity and selectivity of peptide.
23
 Other groups have reported that 
AMPs conjugated to fatty acids with different length ranging from 12 to 18 methylene 
units improved the activity and selectivity of peptide.
24 
 
 
The Parang group recently reported the synthesis of four amphiphilic peptides 
containing positive charge, namely on arginine and lysine residues, conjugated with C14- 
palmitic acid and C16- myristic acid.
23
 Furthermore, Parang’s laboratory synthesized and 
evaluated fatty acylated cyclic polyarginine peptides (ACPPs), such as octanoyl-
[KRRRRR], dodecanoyl-[KRRRRR], and hexadecanoyl-[KRRRRR] as antibacterial 
agents. All fatty acylated cyclic peptides exhibited more potent antibacterial activity than 
the non-acylated cyclic peptide [R]5.
18
  
Efficient intracellular delivery of biological cargos and/ or improving antibacterial 
activity requires systematic design of amphiphilic peptides with sufficient number of 
positively charged amino acids and hydrophobic residues.  In continuation of our efforts 
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to design improved amphiphilic peptides, three class of peptides were synthesized: (1) 
Modified amphiphilic triazolyl cyclic-linear and linear-linear peptides; (2) Amphiphilic 
peptide amide derivatives (APADs); and (3) Amphiphilic fatty acyl triazolyl peptides 
(Figure 1). 
The first section of this chapter describes the synthesis of the modified 
amphiphilic triazolyl peptides (ATPs) using Fmoc solid phase peptides synthesis. The 
peptides incorporate an increased number of propargyl glycine (pG) and tryptophan (W) 
residues. The peptides were then conjugated using click chemistry with arginine-lysine 
(R-K) peptides containing an azide linker to form cyclic-linear [WG(triazol-KR-NH2)]4 
and linear-linear (WG(triazol-KR-NH2))4 amphiphilic triazolyl peptides. The biological 
and physicochemical properties of these peptides will be evaluated and compared with 
the previously synthesized peptides described in Chapter 2.  
 The second section of this chapter describes the synthesis of Amphiphilic Peptide 
Amide Derivatives (APADs). The goal was to compare APADs with the Amphiphilic 
Triazolyl Peptides (ATPs) described in Chapter 1. APADs with amide bond are presumed 
to interact with the membrane with more flexibility compared with rigid triazolyl ring of 
ATPs. By applying Fmoc-based peptide chemistry, APADs were synthesized by coupling 
of tryptophan (W) residues and glutamic acid (E) with different sequence length.  The 
linear and cyclic peptides were conjugated to arginine lysine (R-K) residues through 
amide bond. The biological and physicochemical properties of APADS will be evaluated 
and compared with ATP in future. 
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Finally, the third group of amphiphilic fatty acyl triazolyl peptides was 
synthesized as potential antibacterial agents. These peptides consist of fatty acids with 
different chain lengths of 14 and 18 carbons.  We hypothesized that a new class of 
Amphiphilic Fatty Acyl Triazolyl Peptides (AFTP) with different acyl chain lengths 
could provide novel antibacterial agents. Two fatty acyl derivatives (myristoyl and 
stearoyl) were synthesized in this class. Stearic and myristic acids were conjugated with a 
positively charged peptide containing azide using the click reaction. Their 
characterization and antibacterial activity for these compounds will be evaluated in the 
future.  
Experimental Section 
General 
 All reactions were carried out in Bio-Rad polypropylene columns by shaking and 
mixing in Glass-Col small tube rotator under dry conditions at room temperature unless 
otherwise stated. In general, all peptides in Class I were synthesized and characterized as 
described in chapter 1. All peptides were synthesized using solid-phase techniques. 
commercially available Fmoc amino acids, resins were purchased from Sigma-Aldrich 
Chemical Co. (Milwaukee, WI). The crude peptides were purified by using a reversed-
phase Hitachi HPLC (L-2455) on a Gemini C18 column (250 mm × 21.20 cm, 10 µm) 
and a gradient system. The peptides were separated by eluting the crude peptides at 10.0 
mL/min using a gradient of 0-100% acetonitrile (0.1% trifluoroacetic acid (TFA)) and 
water (0.1% TFA) over 60 min, and then were lyophilized. 
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Synthesis of Linear-Linear (WG(triazole-KR-NH2))4 and Cyclic-Linear 
[WG(triazole-KR-NH2)]4 
 
Synthesis of Linear Peptide (WpG)4 
 The linear peptide was assembled on Rink amide resin (0.59 g, 0.4 mmol, 0.68 
mmol/g) by solid-phase Fmoc/tBu peptide synthesis strategy using Fmoc-protected 
amino acids [Fmoc-Trp(Boc)-OH and Fmoc-L-propargylglycine] (Scheme 1). The linear 
peptide sequence was assembled on the resin after removing the Fmoc group at the N-
terminal in the presence of 20% piperidine in DMF (20% v/v) to obtain the sequence 
NH2-(pG)W(Boc)(pG)W(Boc)(pG)W(Boc)(pG)W(Boc)-Rink amide resin. The resin was 
washed with DMF/DCM and dried under vacuum for 24 h. Reagent R cocktail containing 
trifluoroacetic acid (TFA)/thioanisole/ethandithiol (EDT)/ anisole (90:5:3:2 v/v/v/v, 20.2 
mL) was used to cleave the peptide from the resin. The crude peptide was precipitated by 
adding the filtrates to cold diethyl ether (200 mL, Et2O). The solution was centrifuged at 
4000 rpm for 5 min followed by decantation to obtain the solid precipitate. The peptide 
was lyophilized and purified by reversed-phase HPLC using a gradient system as 
described above to yield solid white coloured linear peptide (W(pG))4 (Scheme 1). 
MALDI-TOF (m/z) [C64H62N12O9]: calcd, 1142.4763 ; found, 1143.3317 [M + H]
+
,  
1181.3810 [M + K]
+
. 
  
Synthesis of Cyclic Peptide [W(pG)]4 
 The linear protected peptide sequence was assembled using H-Trp(Boc)-2-
chlorotrityl resin (0.51 g, 0.4 mmol, 0.78 mmol/g). The resin was swelled using DMF (3 
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× 30 mL, 10 min) followed by coupling with appropriate amino acids (Fmoc-Trp(Boc)-
OH and Fmoc-L-propargylglycine) and deprotection with piperidine in DMF (20% v/v).  
The final N-terminal Fmoc group was removed to assemble the sequence on the peptidyl 
resin, NH2-(pG)W(Boc)(pG)W(Boc)(pG)W(Boc)(pG)W(Boc)-2-chlorotrityl resin 
(Scheme 2). The resin was washed with DMF (3 × 15 mL) and DCM (3 × 15 mL) to 
remove any traces of piperdine. Side chain-protected peptides were cleaved from the 
resins by agitating the peptidyl resin with the cleavage cocktail, acetic acid/ 2,2,2-
trifluoroethanol (TFE)/dichloromethane (1:2:7, v/v/v, 50 mL), for 1 h at room 
temperature followed by filtration and washing the resin with TFE:DCM (2:8 v/v, 20 
mL). The collected filtrate was evaporated to reduce the volume. Hexane (2 × 25 mL) 
and DCM (1 × 25 mL) were added to the residue to remove the acetic acid. The solvents 
were evaporated to yield a fluffy white solid compound that was dried overnight under 
vacuum. The cyclization of the protected crude solid peptide was carried out in the 
presence of a mixture of coupling reagents, 1-hydroxy-7-azabenzotriazole (HOAt) (162 
mg, 0.4 mmol) and N,N-diisopropylcarbodiimide (DIC) (310 µL, 0.4 mmol), in 
anhydrous DMF:DCM (60/200 mL) for 24 h. The solvent was evaporated under reduced 
pressure and the residue was deprotected with reagent R. The cyclization was confirmed 
by mass spectrometry.  All the solvents were removed under reduced pressure that 
generated a high viscous liquid.  
 The final peptide cleavage to remove the side chain protection was carried out by 
shaking the residue with cleavage cocktail, reagent R, TFA/thioanisole/anisole/EDT 
(90:5:2:3 v/v/v/v, 15 mL), for 2 h at room temperture. The crude peptide was precipitated 
by the addition of cold diethyl ether (200 mL, Et2O) and centrifuged at 4000 rpm for 5 
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min followed by decantation to obtain the solid precipitate. The solid material was further 
washed with cold ether (2 × 100 mL). The crude peptide was lyophilized and purified by 
reversed-phase HPLC as described above to yield cyclic peptide [W(pG)]4 (Scheme 2). 
MALDI-TOF (m/z) [C64H60N12O8]: calcd, 1124.4657; found 1147.3156 [M + Na]
+
 , 
1163.3579 [M + K]
+
. 
 
Synthesis of Azide Functionalized Positively Charged Peptide (Ac-K(N3)R-NH2) 
 The peptide was assembled on Rink amide resin (294 mg, 0.2 mmol, 0.68 
mmol/g) by solid-phase peptide synthesis using Fmoc-protected amino acids, Fmoc-
Arg(Pbf)-OH and Fmoc-Lys(N3)-OH. The Rink amide resin was swelled with DCM (50 
mL, 10 min) followed by DMF (50 mL, 2 × 10 min). The Fmoc group on the resin was 
deprotected by piperidine in DMF (20%, v/v, 25 mL, 2 × 10 min) followed by washing 
with DMF (3 × 30 mL). Fmoc-Arg (pbf)-OH (389 mg, 0.2 mmol/g) was then coupled to 
the peptidyl resin in the presence of coupling reagents HBTU (228 mg, 0.2 mmol/g) and 
DIPEA (210 µL) in N,N-dimethylformamide (DMF, 10 mL). The mixture was agitated at 
room tempertuare for 1 h. The resin was then washed with DMF (3 × 10 mL) for 5 min.  
 The Fmoc group was deprotected using using piperidine in DMF (20% v/v, 25 
mL, 2 × 10 min) followed by washing with DMF (3 × 20 mL). The Fmoc-Lys (N3)-OH 
(173 mg, 0.2 mmol) was coupled using HBTU (228 mg, 0.2 mmol) and DIPEA (210 µL) 
in DMF for 1 h. The resin was washed with DMF (3 × 20 mL), and the Fmoc group was 
removed using piperdine in DMF (20% v/v, 25 mL, 2 × 10 min). The resin was washed 
with DMF followed by reacting the the amino group with acetic anhdyride (Ac2O, 95 µL, 
1 mmol) and DIPEA (174 µL, 1 mmol) in anhdyrous DMF (3 mL) for 30 min. 
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  The resin was washed with DMF (3 × 30 mL), DCM (3 × 30 mL), and was dried 
in vaccum overnight before the final cleavage. A freshly prepared cleavage cocktail, 
TFA/triisopropylsilane/water (95:2.5:2.5 v/v/v, 10 mL), was added to the resin and 
shaken at room temperature for 1.5 h. The resin was filtered and evaporated to reduce the 
volume under dry nitrogen. The crude peptide was precipitated by adding cold diethyl 
ether (200 mL, Et2O) and centrifuged at 4000 rpm for 5 min followed by decantation to 
obtain the solid precipitate. The peptide was purified by reversed-phase HPLC using a 
gradient system as described above, and the HPLC fractions were collected, evaporated 
and lyophilized to obtain dry product (Scheme 3). ESI-TOF (m/z) [C14H27N9O3]: calcd, 
369.2237; found, 370.2144 [M  + H]
+
.  
 
Synthesis of Amphiphilic Triazolyl Peptides by Click Chemistry of Peptides (Linear 
or Cyclic) with Azide-Functionalized Positively Charged Linear Peptide 
 The click reaction was carried out in a 20 mL glass vial with small magnetic stir 
bar by adding the alkyne linear peptide (7.46 mg, 8.68 µmol) or cyclic peptide (7.25 mg, 
8.68 µmol)), CuSO4.5H2O (6.5 mg, 0.026 mmole), Cu powder (16.5 mg, 0.26 mmol), 
sodium ascorbate (51.5 mg, 0.26 mmol), and azide-functionalized peptide, Ac-K(N3)R-
NH2 (10 mg, 0.026 mmol) in methanol:water (2:1v/v, 5 mL) followed by addition of 
DIPEA (9 µL, 0.052 mmol). The mixture was stirred at room temperature for 24-48 h. 
The completion of the reaction was confirmed by MALDI mass spectroscopy. The 
reaction mixture was filtered, and the solvent was evaporated under reduced pressure to 
afford the crude product. The crude product was further purified by HPLC using a 
gradient system as described above, and the HPLC fractions were collected, evaporated 
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and lyophilized to obtain solid compounds (Schemes 4 and 5). Cyclic-linear 
[WG(triazole-KR-NH2)]4, MALDI-TOF (m/z) [C120H168N48O20]:  calcd, 2601.3605; 
found 2621.1569 [M + H + H2O]
+
; Linear-linear (WG(triazole-KR-NH2))4 MALDI-TOF 
(m/z) [C120H170N48O21]:  calcd, 2619.3710; found 2621.1569 [M + 2 ]
+
, 2637.5587 [M + 
H2O]
+
. 
 
Amphilphilic Peptide Amide Derivatives  
 
Synthesis of Linear Peptide (WE)3 
 The linear peptide was assembled on Rink amide resin (425 mg, 0.47 mmol, 1.1 
mmol/g) by solid-phase Fmoc/tBu peptide synthesis strategy using Fmoc-protected 
amino acids [Fmoc-Trp(Boc)-OH (315 mg, 0.2 mmol) and Fmoc-L-glutamic acid (225 
mg, 0.2 mmol) (Scheme 6). The linear peptide sequence was assembled on the resin after 
removing the Fmoc group at the N-terminal in the presence of 20% piperidine in DMF 
(v/v) to obtain the sequence NH2-(E)W(Boc)(E)W(Boc)(E)W(Boc)-Rink amide resin. 
The resin was washed with DMF/DCM and dried under vacuum for 24 h. Reagent R was 
used to cleave the peptide from the resin. The crude peptide was precipitated by adding 
filtrates to cold diethyl ether (200 mL, Et2O).  The resulting solution was centrifuged at 
4000 rpm for 5 min followed by decantation to obtain the solid precipitate. The peptide 
was lyophilized and purified by reversed-phase HPLC using a gradient system as 
described above to yield solid white colored linear peptide (WE)3 (Scheme 6). MALDI-
TOF (m/z) [C48H54N10O12]: calcd, 962.3923 ; found, 986.6340 [M + Na]
+
, 1002.6207 [M 
+ K]
+
. 
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Synthesis of Cyclic Peptide [WE]3 
The linear protected peptide sequence was assembled using H-Trp(Boc)-2-
chlorotrityl resin (512 mg, 0.78 mmol, 1.5 mmol/g). The resin was swelled in DMF (3 × 
30 mL, 10 min) followed by coupling with appropriate amino acids (Fmoc-Trp (Boc)-OH 
(632 mg, 0.4 mmol) and Fmoc-L-glutamic acid (638.25 mg, 0.4 mmol) and deprotection 
cycle with piperidine in DMF (20% v/v). The final N-terminal Fmoc group was removed 
to assemble the desired sequence NH2-(E)W(Boc)(E)W(Boc)(E)W(Boc)-2-chlorotrityl 
resin (Scheme 7).  The resin was washed with DMF (3 × 15 mL) and DCM (3 × 15 mL) 
to remove any traces of piperdine. Side chain-protected peptides were cleaved from the 
resins by agitating the peptidyl resin with cleavage cocktail, acetic acid/ 2,2,2-
trifluoroethanol (TFE)/dichloromethane (1:2:7, v/v/v, 50 mL), for 1 h at room 
temperature followed by filtration and washing the resin with TFE:DCM (2:8 v/v, 20 
mL). The collected filtrate was evaporated to reduce the volume. Hexane (2 × 25 mL) 
and DCM (1 × 25 mL) were added to the residue to remove the acetic acid from the 
residue. The solvents were evaporated to yield a fluffy white solid compound that was 
dried overnight.  
The cyclization of the protected crude solid peptide was carried out in the 
presence of a mixture of the coupling reagents 1-hydroxy-7-azabenzotriazole (HOAt) 
(162 mg, 0.4 mmol) and N,N-diisopropylcarbodiimide (DIC) (310 µL, 0.4 mmol) in 
anhydrous DMF:DCM (60/200 mL) for 24 h. The solvent was evaporated from a sample 
solution (5 mL) under reduced pressure. Mass spectrometry confirmed the cyclization in 
the residue.  
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Thus, all the solvents were removed under reduced pressure that generated a high 
viscous liquid. The final peptide cleavage to remove the side chain protection was carried 
out by shaking the residue with cleavage cocktail, reagent R, 
TFA/thioanisole/anisole/EDT (90:5:2:3 v/v/v/v, 15 mL) for 2 h at room temperature. The 
crude peptide was precipitated by the addition of cold diethyl ether (200 mL, Et2O) and 
centrifuged at 4000 rpm for 5 min followed by decantation to obtain the solid precipitate. 
The solid material was further washed with cold ether (2 × 100 mL). The crude peptide 
was lyophilized and purified by reversed-phase HPLC (Hitachi L-2455) as described 
above to yield cyclic peptide [WE]3 (Scheme 7). MALDI-TOF (m/z) [C48H51N9O12]: 
calcd, 945.3657; found 968.1992 [M + Na]
+
. 
 
Synthesis of Amino Functionalized Positively Charged Peptide (Ac-KR-NH2) 
 The peptide was assembled on Rink amide resin (294 mg, 0.2 mmol, 0.68 
mmol/g) by solid-phase peptide synthesis using Fmoc-protected amino acids, Fmoc-
Arg(Pbf)-OH and Fmoc-Lys-OH. The Rink amide resin was swelled with DCM (50 mL, 
10 min) and then DMF (50 mL, 2 × 10 min). The Fmoc group on the resin was 
deprotected by piperidine in DMF (20%, v/v, 25 mL, 2 × 10 min) followed by washing 
with DMF (3 × 30mL). Fmoc-Arg (pbf)-OH (389 mg, 0.2 mmol/g) was then coupled to 
the peptidyl resin in the presence of HBTU (228 mg, 0.2 mmol/g) and DIPEA (210 µL) 
in N,N-dimethylformamide (DMF, 10 mL). The mixture was agitated at room 
temperature for 1 h. The resin was then washed with DMF (3 × 10 mL) for 5 min. The 
Fmoc group was deprotected using using piperidine in DMF (20% v/v, 25 mL, 2 × 10 
min) followed by washing with DMF (3 × 20 mL).  
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 The Fmoc-Lys-OH (173 mg, 0.2 mmol) was coupled by using HBTU (228 mg, 
0.2 mmol), DIPEA (210 µL) in DMF for 1 h. The resin was washed with DMF (3 × 20 
mL), and Fmoc group was deprotected by using piperdine in DMF(20% v/v, 25 mL, 2 × 
10 min). The resin was washed with DMF, and the amino group was acetylated by 
reaction with acetic anhdyride (AC2O, 95 µL, 1 mmol) and DIPEA (174 µL, 1 mmol) in 
anhdyrous DMF (3 mL) for 30 min. The resin was again washed with DMF (3 × 30 mL), 
DCM (3 × 30 mL), and then dried in vaccum overnight before the final cleavage. A 
freshly prepared cleavage cocktail, TFA/ triisopropylsilane/ water (95:2.5:2.5 v/v/v, 10 
mL), was added to the resin and shaken at room temperature for 1.5 h.  
 The resin was filtered and the filtrate was evaporated to reduce the volume under 
dry nitrogen. The crude peptide was precipitated by adding cold diethyl ether (200 mL, 
Et2O) and centrifuged at 4000 rpm for 5 min followed by decantation to obtain the solid 
precipitate. The peptide was purified by reversed-phase HPLC using a gradient system, 
and lyophilized to obtain the desired product (Scheme 8). ESI-TOF (m/z) [C14H29N7O3]: 
calcd, 343.4354; found, 343.2140 [M]+.  
 
Coupling of Amphiphilic Peptides (WE)3 and [WE]3 with Amino-Functionalized 
Positively Charged Peptide (Ac-KR-NH2) via an Amide Bond. 
 The reaction was carried out in 20 mL round flask with small magnetic stir bar 
by adding the amphiphilic peptide linear peptide (WE)3 (10 mg, 0.01 mmol) or cyclic 
peptide [WE]3 (7.0 mg, 0.01 µmol), HOBT (1.8 mg, 0.01 mmole), benzotriazol-1-
yloxy) tripyrrolidino-phosphonium hexafluorophosphate (PyBOP, 14 mg, 0.1 mmol), 
DIPEA (14 µL, 0.01 mmol), and amino-functionalized peptide, Ac-KR-NH2 (10.85 
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mg, 0.01 mmol) in 2 mL of DMF. The mixture was stirred at room temperature for 1-2 
h. The completion of the reaction was confirmed by MALDI mass spectroscopy. The 
reaction mixture was filtered, and the solvent was evaporated under reduced pressure 
to afford the crude product. The crude product was further purified by HPLC using a 
gradient system, and the desired compound was lyophilized to dryness (Scheme 9). 
Linear-linear (WE(AC-KR-NH2))3, MALDI-TOF (m/z) (C90H138N31O18): Calcd, 
1938.0601; found 1954.1202 [M + H2O]
+
. Cyclic-linear [WG(AC-KR-NH2)]3 
MALDI-TOF (m/z) [C90H132N30O18]: Calcd, 1921.0336; found 1925.0213 [M + 4H]
+
.  
 
Amphiphilic Fatty Acyl Triazolyl Peptides  
Synthesis of Stearic Propargyl Amide 
Stearic acid (284.48 mg, 2.48 mmol) and hydroxybenzotriazole (HOBT, 544 mg, 
0.4 mmol) were dissolved in 20 mL of anhydrous tetrahydrofuran (THF). Propargylamine 
(160 µl, 2.50 mmol) was then added to the reaction at room temperature and the mixture 
was cooled to 0 °C. A solution of dicyclohexylcarbodiimide (DCC) (511 mg, 2.48 mmol) 
in 15 mL of anhydrous THF was added, and the mixture was stirred for 2 days at room 
temperature. The reaction was monitored by TLC with hexane/ ethyl acetate 7:3 v/v as 
the mobile phase. The reaction was filtered and the solvent was removed under reduced 
pressure. Dichloromethane (250 mL) was added and the organic phase was washed three 
times with 1 M of KHSO4 solution followed by three times with 1 M NaHCO3. The 
organic layer was separated, and the solvent was removed under reduced pressure. The 
resulting white solid was purified by recrystallization from ethanol (yield 75%), a white 
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solid N-propargyl stearic amide (Scheme 10). MALDI-TOF (m/z) (C21H39NO): Calcd, 
321.3032; found 322.2315 [M + H]
+
. 
 
Synthesis of Myristic Propargyl Amide 
Myristic acid (228.37 mg, 0.043 mmol) and hydroxybenzotriazole (HOBT, 654 
mg, 4.3 mmol) were dissolved in 40 mL of anhydrous tetrahydrofuran (THF). 
Propargylamine (275 µl, 2.50 mmol) was added to the reaction and the mixture was then 
cooled to 0 °C. A solution of DCC (888 mg, 4.3 mmol) in 25 mL of anhydrous THF was 
added, and the mixture was stirred for 2 days at room temperature. The reaction was 
monitored by TLC with hexane/ethyl acetate 7:3 v/v as the eluent. The mixture was then 
filtered, and the solvent was removed under reduced pressure. Dichloromethane (250 
mL) was added, and the organic phase was washed three times with 1 M of KHSO4 
solution followed by three times with 1 M NaHCO3. The organic layer was concentrated 
under reduced pressure and the resulting white solid was purified by recrystallization 
from ethanol (yield around 75%), a white solid N-propargyl myristic amide (Scheme 10). 
MALDI-TOF (m/z) (C17H31NO): Calcd, 265.2406; found 266.2345 [M + H]
+
. 
 
Synthesis of Protected Positively Charged Peptidyl Resin Functionalized with Azide  
The peptide was assembled on Rink amide resin (294 mg, 0.2 mmol, 0.68 
mmol/g) by solid-phase peptide synthesis using Fmoc-protected amino acids, Fmoc-
Arg(Pbf)-OH and Fmoc-Lys(N3)-OH.The Rink amide resin was swelled with DCM (50 
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mL, 10 min) and then DMF (50 mL, 2 × 10 min). The Fmoc group on the resin was 
deprotected by piperidine in DMF (20%, v/v, 25 mL, 2 × 10 min) followed by washing 
with DMF (3 × 30 mL). Fmoc-Arg (Pbf)-OH (389 mg, 0.2 mmol/g) was then coupled to 
the peptidyl resin in the presence of HBTU (228 mg, 0.2 mmol/g) and DIPEA (210 µL) 
in N,N-dimethylformamide (DMF, 10 mL). The mixture was agitated at room 
temperature for 1 h. The resin was then washed with DMF (3 × 10 mL) for 5 min. The 
Fmoc group was deprotected using piperidine in DMF (20% v/v, 25 mL, 2 × 10 min) 
followed by washing with DMF (3 × 20 mL). Fmoc-Lys (N3)-OH (173 mg, 0.2 mmol) 
was coupled using HBTU (228 mg, 0.2 mmol), DIPEA (210 µL) in DMF for 1 h. The 
resin was washed with DMF (3 × 20 mL), and Fmoc group was deprotected by using 
piperdine in DMF (20% v/v, 25 mL, 2 × 10 min). The resin was washed with DMF 
followed by acetylating the amino group in the presence of acetic anhdyride (Ac2O, 95 
µL, 1 mmol) and DIPEA (174 µL, 1 mmol) in anhdyrous DMF (3 mL) for 30 min. The 
resin was washed with DMF (3 × 30 mL), DCM (3 × 30 mL), and was dried under 
vaccum overnight before the final cleavage. The peptide-attached resin remained 
protected for coupling with fatty propargyl stearyl and myristoyl amide (Scheme 11). 
MALDI-TOF (m/z) (C43H58N9O9S): Calcd, 876.4078; found 877. 0532 [M + H]
+
. 
 
Click Reaction of Fatty Propargyl Amide with Positively Charged Arginine Azide 
Click reaction was carried out in 20 mL round bottom flask with small magnetic 
stir bar. Protected arginine azide (530 mg, 0.25 mmol) was swelled in DMF (50 mL × 3 
for 10 min). Next, CuBr (18 mg, 0.13 mmol), sodium ascorbate (75 mg, 0.13 mmol), 
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DIPEA (218 µl, 0.13 mmol), 2,6-lutidine (145µl, 0.13 mmol), stearic propargyl peptide 
(120 mg, 0.125 mmol) or myristic propagyl peptide (99 mg, 0.125 mmol) were added. 
The mixture was stirred at room temperature for 24-48 h. The completion of the reaction 
was confirmed by MALDI mass spectroscopy. The reaction mixture was filtered, and the 
solvent was evaporated under reduced pressure to afford the crude product. The crude 
product was further purified by HPLC using a gradient system as described above, and 
the HPLC fractions were collected, evaporated and lyophilized to obtain solid 
compounds. Stearic Acyl Triazolyl peptide MALDI-TOF (m/z) [C35H66N10O4]: calcd, 
690.5612; found 691.1710 [M + H]
+ 
(Scheme 11);  Myristic Acyl Triazolyl peptide 
MALDI-TOF (m/z) [C31H58N10O4]: calcd, 634.8725; found 635.0931 [M + H]
+ 
. 
 
Results and Discussion 
 We reported the synthesis of amphiphilic linear and cyclic peptides containing 
tryptophan (W) and arginine (R) connected through trizaole ring with proparglyglycine 
(PG) in Chapter I. The compounds were characterized and evaluated for their potential 
role as drug delivery tools. The peptides did not show any efficiency in improving the 
cellular uptake possibly because of the limited number of three positively charged amino 
acids in each peptide. Thus, there is a need to optimize amphiphilic peptides by 
increasing the number of positive charged residues and hydrophobic residues to improve 
the cell penetrating property of the peptides and to enhance the intracellular delivery of 
bioactive compounds.  
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To address the above issue, three classes of compounds were synthesized. In Class 
I, linear-linear (WG(triazole-K(N3)R-NH2))4 and cyclic-linear [WG (triazole-K(N3)R-
NH2)]4 containing L-amino acids were synthesized using Fmoc-based peptide chemistry. 
The linear peptide sequence (WpG)4 was assembled on the Fmoc-Rink amide resin using 
solid-phase synthesis strategy. The last Fmoc group on the N-terminal was deprotected by 
piperidine (20% v/v, DMF). Then the resin was dried, washed, and cleaved to afford the 
linear peptide, which was purified by reversed-phase HPLC (Scheme 1). Synthesis of 
cyclic peptide was accomplished by assembling of the linear protected peptide (WpG) on 
the H-Trp (Boc)-2-chlorotrityl chloride resin. The side chain protected group was 
removed, and the peptide was again purified using HPLC (Scheme 2). The synthesis of 
azide-functionalized positively charged peptide building block (Ac-K(N3)R-NH2) was 
performed on Rink amide resin. The Fmoc group was deprotected, and amino group was 
acetylated using acetic anhydride in DMF. The peptide was cleaved from the resin and 
purified by HPLC to afford Ac-K(N3)R-NH2 (Scheme 3).  
 Click chemistry reactions were performed by coupling linear-linear and cyclic-
linear peptides containing alkyne, (W(pG))4 and [W(pG)]4, and the azide-functionalized 
linear peptide Ac-K(N3)R-NH2 in solution phase using CuSO4
.
5H2O, Cu powder, sodium 
ascorbate, and N,N-diisopropylethylamine (DIPEA) in methanol:water for 24-48 h. The 
formation of the conjugated products was confirmed by MALDI-TOF mass spectroscopy 
(Schemes 4 and 5).   
 In Class II, new amphiphilic peptides amide derivatives were synthesized. The 
purpose was to compare the triazole peptides derivatives with the corresponding amide 
peptides for their role as molecular transporter. Linear and cyclic tryptophan and glutamic 
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acid containing peptides were connected through amide bonds with the lysine residue in 
Ac-KR-NH2. Linear-linear (WE(AC-KR-NH2))3 and cyclic-linear [WE(AC-KR-NH2)]3 
peptides were again synthesized using Fmoc-based peptide chemistry. The linear peptide 
sequence (WE)4 was assembled on the Fmoc-Rink amid resin using solid-phase synthesis 
strategy. The last Fmoc group on the N-terminal was deportected by piperidine (20% v/v, 
DMF). Then the resin was dried, washed, and cleaved to afford the linear peptide which 
was purified by reversed-phase HPLC (Scheme 6). Synthesis of cyclic peptide was 
accomplished by assembly of the linear protected peptide (WE)4 on the H-Trp(Boc)-2-
chlorotrityl chloride resin. The side chain protected group was removed, and the peptide 
was purified using HPLC (Scheme 7).  
 The synthesis of functionalized positively charged peptide building block (Ac-
KR-NH2) was performed on Rink amide resin. The Fmoc group was deprotected, and 
amino group was acetylated using acetic anhydride in DMF. The peptide was cleaved 
from the resin and purified by HPLC to afford Ac-KR-NH2 (Scheme 8). The coupling 
reaction was performed by adding (WE)3 and [WE]3, and an amino-functionalized 
peptide, Ac-KR-NH2, in DMF in the presence of the coupling reagents HOBT, PyBOP, 
DIPEA.  After HPLC purification, the formation of the product was confirmed by 
MALDI-TOF mass spectroscopy (Scheme 9). 
 In Class III, two Amphiphilic Fatty Acyl Triazolyl Peptides (AFTP) derivatives 
were synthesized using peptides containing arginine and lysine azide (AC-K(N3)R-NH2). 
Myristic acid and stearic acid were coupled to propagylamine in the presence of HOBT in 
THF. Positively charged peptidyl resin functionalized with an azide group was 
synthesized by assembling the peptide on Rink amide resin using Fmoc-Arg(Pbf)-OH 
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and Fmoc-Lys(N3)-OH. After Fmoc removal and capping of the peptides by acetic 
anhdyride, click chemistry was used to react the myristic propargyl and stearic propargyl 
amides in the presence of CuBr, sodium ascorbate to afford the stearic triazolyl peptide 
and myristic triazolyl peptides (Schemes 10 and 11). 
 
Conclusion  
 In conclusion, three classes of amphiphilic peptides were synthesized to be 
evaluated as molecular transporters and antibacterial agents. Fmoc-based peptide 
synthesis, click chemistry, and amide bond formation were used in the synthesis of 
compounds. In the future, the physicochemical properties, cytotoxicity, nanostructure 
formation, molecular transporter efficiency, and antibacterial activity of these compounds 
will be evaluated and compared with linear-linear (WG(triazole-KR-NH2))3 and cyclic-
linear [WG(triazole-KR-NH2)]3 in Manuscript I. 
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Figure legends.  
 
Figure 1. Chemical structures of three classes of amphiphilic peptides. 
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Scheme Legends: 
 
Scheme 1. Synthesis of linear (W(pG))4. 
Scheme 2.  Synthesis of cyclic [W(pG)]4.   
 Scheme 3. Synthesis of positively charged peptides containing an azide. 
Scheme 4. Click Chemistry of to react the propargyl groups on a linear peptide with 
azides on a positively charged peptide. 
Scheme 5. Click Chemistry of to react the propargyl groups on a cyclic peptide with 
azides on a positively charged peptide. 
Scheme 6. Designing of linear (WE)3 amide derivatives of amphiphilic peptides. 
Scheme 7. Designing of cyclic [WE]3 amide derivatives of amphiphilic peptides. 
Scheme 8. Synthesis of positively charged peptides with arginine and lysine residues. 
Scheme 9. Coupling of cyclic amphiphilic peptides by creation of an amide bond. 
Scheme 10. Synthesis of stearyl propargyl amide and myristyl propargyl amide 
building blocks. 
Scheme 11. Synthesis of positively charged protected peptidyl resin functionalized 
with azide and click chemistry to react fatty acyl propargyl amides with azides on 
arginine containing units. 
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 111 
 
 
Scheme 10.  
 
 
 
  
                                                                                                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 112 
 
Scheme 11.  
 
 
 
 
                                                                                                                              
